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Miodrag Vrbic, Maja Jovanovic, Lidija Popovic-Dragonjic, Aleksandar Rankovic, Marina Djordjevic-Spasic  
Clinic for Infectious Diseases, Clinical Centre Niš, Serbia 
Abstract. The number of CD4 lymphocytes defines the evolutional stage of HIV-infection and is the most important for a 
reliable estimation of the individual risk of developing AIDS. However, it is difficult to predict the degree of immune 
reconstitution during antiretroviral therapy, as it varies significantly from one person to another. Further investigations 
to better understand the limitations of immunological success are necessary to improve the response to treatment and 
regimen durability. The current study includes HIV-infected patients in Southeastern Serbia with achieved virologic 
suppression of HIV infection. The CD4 count was determined by flow cytometry, and was correlated with the duration of 
treatment, initial number of CD4 cells, type of antiretroviral therapy, mode of transmission of infection, age and gender 
of examinees. The resulting arithmetic mean and standard deviation of CD4 number was 473±259 cells/µl (range, 1130 
cells/µl). There was no statistically significant correlation between the values of CD4 count and length of treatment, 
stage of the infection at which the therapy was started, treatment profile, method of infection, age or gender. The 
obtained results are comparable with the existing studies that follow immunological response to antiretroviral therapy 
and primarily point out the issue of substantial individual response variability, which has not yet been fully elucidated. 
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Introduction

 
During an HIV infection, the complex immunopathoge-
netic relationship of viral replication, destruction of in-
fected CD4 lymphocytes, and immune response status 
passes through three phases. The primary infection 
phase is characterized by a massive viremia, drop of 
CD4 count, and induction of, primarily, virus-specific 
cytotoxic lymphocytes. After a period of several weeks 
up to several months, the parameters find a kind of bal-
ance among them and maintain it during the chronic 
phase of clinical latency. Its highly variable duration, 
from only a couple of years to even over 15 years, is 
characterized by progressive anatomical and functional 
damage to the lymphatic tissue. Eventually, the inability 
to maintain HIV-specific immune response results in a 
repeated viral load increase and drop of CD4 count, 
with the development of the acquired immune defi-
ciency syndrome (AIDS), and presentations of oppor-
tunistic infections and tumors. 
Combination antiretroviral therapy (cART) substan-
tially reduces the incidence of AIDS and mortality, and 
now the World Health Organization consolidated 
guidelines that favor the use of HIV viral load (VL) 
monitoring for routine identification of its efficacy [1]. 
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However, the monitoring of immunological response to 
treatment (defined as an increase in CD4 cell count) 
remains an important clinical tool, being significantly 
and independently associated with improved prognosis. 
Two reference values are generally accepted: above 
400-500 CD4 cells/µl, severe AIDS-related diseases are 
very rare; below 200 CD4 T cells/µl, the risk of AIDS-
related morbidity increases with increased duration of 
immunosuppression. 
However, it is difficult to predict the degree of im-
mune reconstitution, as it varies significantly from one 
person to another. Hence, the precise definition of the 
success of an immunological treatment does not exist at 
the moment, and depending on the study it is taken to be 
an increase of 50, 100 or 150 CD4 T cells/µl per year 
[2,3]. 
In such a situation, further investigations to better 
understand the limitations of immunological success are 
necessary to improve individual responses to treatment 
and regimen durability. 
Material and Methods 
The study included patients on the cART, with achieved 
virologic suppression of HIV infection (HIV-VL < 50 
copies/ml) [4], in whom the number of CD4 cells was 
determined by flow cytometry (BD FACS Count™). 
The patients in whom reduced CD4 lymphocyte 
counts could be the consequence of concomitant condi-
tions, such as liver cirrhosis, autoimmune diseases, or 
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immunosuppressive treatments, were excluded from the 
study. 
Due to possible fluctuations in individual measure-
ments, only those results were taken into account that 
were consistent with previous CD4 count control meas-
urements, usually performed in six-month intervals. 
The obtained results were displayed individually on 
the scatter diagram, in relation to the duration of treat-
ment, and were also expressed by overall arithmetic 
mean with standard deviation. The significance of the 
correlation of their values with treatment duration, ini-
tial number of CD4 cells (stage of infection at which 
cART was started), type of cART, mode of transmission 
of infection, age and gender of patients, were deter-
mined by Student's t-test and a correlation coefficient r. 
The study was conducted at the Clinic for Infectious 
Diseases - Clinical Center Niš, the reference center for 
HIV-infection treatment in the region of Southeastern 
Serbia. 
Results 
The study involved 58 patients, 44 (76%) men and 14 
(24%) women, with the following age distribution: 12 
(20%) aged 20 to 30 years, 21 (36%) aged 30 to 40 
years, 13 (23%) aged 40 to 50 years, 8 (14%) aged 50 to 
60, and 4 (7%) aged above 60 years of age. 
In relation to the mode of transmission, 15 (26%) 
examinees were infected via intravenous drug abuse, 26 
(44%) via homosexual intercourse (MSM), 12 (21%) 
via heterosexual intercourse, 1 (2%) via blood transfu-
sion, while in 4 (7%) patients the mode of transmission 
could not be established. 
Combination ART was started in 40 (69%) exami-
nees with CD4 lymphocyte counts ≤200/µl, and in 18 
(31%) examinees with CD4 counts >200/µl. In 28 
(48%) cases, it was based on protease inhibitors (PI), 
and in 30 (52%) on non-nucleoside reverse transcriptase 
inhibitors (NNRTI). 
Individual results of CD4 count measurements were 
correlated with the duration of cART, with the final 
presented value involving all the patients with ≥10 years 
of treatment (Figure 1). The arithmetic mean with standard 
deviation of cART duration was 5.72±3.32 years.  
The arithmetic mean with standard deviation of CD4 
lymphocyte count was 473±259 cells/µl, (range, 1130 
cells/µl) (Figure 1). Most of the examinees (33; 57%) 
had CD4 counts ≤500/µl, while 25 (43%) examinees 
had CD4 counts ≥500/µl. Of the total number, 10 (17%) 
examinees had ≤200 CD4 cells/µl, 3 out of 8 patients 
(37%) at the beginning of treatment (in the first cART 
year), and 7 (14%) out of the remaining 50 examinees 
after ≥3 years of treatment. 
The association of CD4 cell counts per µl with 
cART duration was not statistically significant. There 
was not any statistically significant difference in CD4 
counts related to the initial number of CD4 cells (p > 
0,05), type of cART, mode of transmission of infection, 
age and gender of patients. 
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Fig. 1 Individual counts of CD4 cells/µl (y - axis) re-
lated to the duration of ART in years (x - axis), 
with arithmetic mean of CD4 counts in cells/µl. 
Discussion   
The average number of 467 CD4 cells/µl obtained in the 
study and absence of complete recovery of the immune 
system in most of the patients (43% examinees ≥500 
cells/µl, 57% examinees <500 cells/µl) corresponds to 
the results presented in numerous studies of immune 
reconstitution after multiannual antiretroviral therapy 
followed by a complete virologic response [5,6,7,8]. 
Since CD4 counts after several years of treatment 
achieve a plateau, characterized by small or absent in-
creases, the connection between these two parameters 
was not evaluated in the above studies. , The present 
study, on the other hand, included patients at the begin-
ning of cART, when the dynamics of change in CD4 
lymphocyte counts was most conspicuous – usually  
characterized by a rapid increase in the number of cir-
culating CD4 cell lymphocytes during the first 2-3 
months of treatment (median of 21.2 cells/μl per 
month), representing mainly a redistribution of activated 
CD4 memory cells previously sequestered in the lym-
phoid tissue and generalized reduction in apoptotic cell 
death, followed by a slower second phase of CD4 cell 
expansion (5.5 cells/μl per month), representing the 
expansion of naive CD4 cells [9]. 
However, that did not produce any significant 
change in the overall study results, nor did it reveal any 
significant association of CD4 lymphocytes with treat-
ment duration. A possible explanation could be, ac-
cording to recent recommendations, an earlier initiation 
of treatment (regardless of CD4 count), and now a re-
duced number of presentations with advanced HIV dis-
ease (3 of the 8 patients, i.e. 37%). A smaller percentage 
of late presenters has also been reported in different 
European and US studies [10,11,12]. 
The remaining 7 out of 50 examinees in whom CD4 
counts were below 200/μl after multiannual treatments, 
belonged to the group of immunological non-respond-
ers. Their prevalence of 14% was comparable with the 
results of other studies of such a discordant immune 
response, where satisfactory immune status could not be 
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achieved despite prolonged viral suppression [13]. The 
consequences of this condition in the long run are not 
yet clear [14,15]. The data from the relevant clinical  
surveys suggest that mortality seems to be slightly higher, 
but has not been related to AIDS-defining diseases, the 
increased incidence of which is present only in the first 
few months of therapy [16]. The exact background of this 
discordant response is also unclear, and DHHS guidelines 
do not recommend switching an otherwise suppressive 
cART regimen in this patient group [17]. 
In general, the risk factors for the lack of immunologic 
response are heterogenous and often unmodifiable. Firstly, 
a complete reconstitution of the immune system is only 
rarely possible if the patient’s initial situation is poor (the 
worse the immune system, the more unlikely a complete 
recovery), and viral suppression over several years cannot 
change that [6,8,18]. Forty-four percent of patients with 
less than 100 CD4 cells/μl at the initiation of cART failed 
to reach 500 CD4 cells/μl even after a decade of virologic 
successful treatment, while 25% of patients with 100-200 
CD4 cells/μl still showed that risk [14,19]. The trials of 
several thousand patients confirmed a connection of the 
initial CD4 count with the level of an immune response, as 
suggested by their correlation as well at the borderline of 
statistical significance (p > 0.05), which was verified by 
the presented study of a much smaller number of subjects. 
Age may also play a role. In older patients, immu-
nological response is often only moderate, mainly due 
to thymic degeneration [20,21]. This observation has 
not been confirmed by the present study either, probably 
due to the same reasons as for the impact of low number 
of initial CD4 cells. On the other hand, these results in a 
small number of patients indicate a substantial individ-
ual variability of the above-mentioned risk factors for 
poor immune response.  
Other reasons that could possibly explain the wide 
range of immune responses (1130 cells/µl in the present 
study), such as gender, mode of transmission of infec-
tion, or the difference between NNRTIs- and PI-based 
cART, were not associated with CD4 counts in the cur-
rent study, as confirmed in other studies in the past 
[22,23].  
Conclusion 
Alongside viral load, measurement of the CD4 cells 
level is the most important parameter or surrogate 
marker in HIV medicine. As the strongest predictor of 
HIV progression, allowing for a reliable estimation of 
the individual risk of developing AIDS, it is of vital 
importance for the patients. 
Having in mind that variability of CD4 expression 
among patients is still completely unresolved, further 
efforts to improve the understanding of the success and 
failure of an immune response would have implications 
not only for HIV infection, but could also possibly help 
in the interpretation of the role of cellular immunity in 
other diseases. 
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